Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

by Kerry S. Campbell, Adam D. Cohen, Tatiana Pazina, Tatiana Pazina
Published 2018-11-01

Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma

by Tatiana Pazina, Alexander W. MacFarlane, Luca Bernabei, Essel Dulaimi, Rebecca Kotcher, Clinton Yam, Natalie A. Bezman, Michael D. Robbins, Eric A. Ross, Kerry S. Campbell, Adam D. Cohen
Published 2021-01-01

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

by Tatiana Pazina, Ashley M. James, Alexander W. MacFarlane, Natalie A. Bezman, Karla A. Henning, Christine Bee, Robert F. Graziano, Michael D. Robbins, Adam D. Cohen, Kerry S. Campbell
Published 2017-09-01